ABBOTT LABORATORIES

ABT · CIK 0000001800

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$44.33B5.7%

FY2025

Net income (FY)

$6.52B51.3%

FY2025

Free cash flow (FY)

$7.39B16.4%

FY2025

Diluted EPS (FY)

$3.7251.3%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 1.7× since FY2007 · net margin 22.1% → 14.7%

MarginsNet marginFCF margin

FY2025: net 14.7% · free cash flow 16.7% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $9.57B operating cash − $2.17B capex = $7.39B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 19% (FY2011) → 13% (FY2025) · on assets 7.5%

The receipts

ABBOTT LABORATORIES

ABT · CIK 0000001800

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$44.33B5.7%

FY2025

Net income (FY)

$6.52B51.3%

FY2025

Free cash flow (FY)

$7.39B16.4%

FY2025

Diluted EPS (FY)

$3.7251.3%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 1.7× since FY2007 · net margin 22.1% → 14.7%

MarginsNet marginFCF margin

FY2025: net 14.7% · free cash flow 16.7% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $9.57B operating cash − $2.17B capex = $7.39B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 19% (FY2011) → 13% (FY2025) · on assets 7.5%

The receipts